Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines
- 1 August 1996
- Vol. 120 (2), 174-181
- https://doi.org/10.1016/s0039-6060(96)80285-6
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity.The Journal of Immunology, 1994
- Tumor-rejection antigens recognized by T lymphocytesCurrent Opinion in Immunology, 1993
- Immunotherapy Via Gene TherapyJournal of Immunotherapy, 1993
- Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells.The Journal of Experimental Medicine, 1993
- Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells.The Journal of Immunology, 1993
- Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma CellsScience, 1993
- Cancer statistics, 1993CA: A Cancer Journal for Clinicians, 1993
- Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4Science, 1991
- T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes.The Journal of Immunology, 1991
- Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity.The Journal of Experimental Medicine, 1990